Logotype for NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company (NAMS) investor relations material

NewAmsterdam Pharma Company Piper Sandler 37th Annual Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for NewAmsterdam Pharma Company N.V.
Piper Sandler 37th Annual Healthcare Conference summary4 Dec, 2025

Conference highlights

  • Record attendance achieved for the 37th annual event, reflecting strong industry engagement.

  • Key sessions featured updates on major cardiovascular outcome trials and regulatory progress.

  • Presentations emphasized the importance of data transparency and stakeholder communication.

  • Discussions included the evolving landscape of dyslipidemia management and patient perspectives.

  • The event fostered collaboration between clinical leaders, analysts, and commercial partners.

Clinical trial updates and timelines

  • PREVAIL CVOT is on track for a readout in the second half of 2026, with a mid-2026 update planned.

  • Event rates are closely monitored; lower-than-expected rates may indicate greater drug efficacy.

  • BROADWAY and BROOKLYN studies published in leading journals, showing significant MACE reduction.

  • TANDEM study (PCSK9 combo) and RUBIN diabetes trial are both expected to read out in 2026.

  • HORIZON trial is anticipated to read out before PREVAIL, likely in the first half of 2026.

Regulatory and commercial strategy

  • EMA accepted filings for LDL-C monotherapy and fixed-dose combo; Menarini is preparing for launch.

  • Menarini's extensive sales force and medical affairs team are key to European commercialization.

  • U.S. NDA filing targeted for the first half of 2026, with efforts to maximize label at launch.

  • Pricing strategies are under scenario planning, considering value in LDL, Lp(a), diabetes, and Alzheimer's.

  • Launch timing aims to align with key data releases for optimal market impact.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next NewAmsterdam Pharma Company earnings date

Logotype for NewAmsterdam Pharma Company N.V.
Q4 202526 Feb, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next NewAmsterdam Pharma Company earnings date

Logotype for NewAmsterdam Pharma Company N.V.
Q4 202526 Feb, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company based in the Netherlands, focusing on the development of oral and non-statin medicines for patients at high risk of cardiovascular disease. Its leading product candidate is obicetrapib, a next-generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, currently in various stages of clinical trials. The company's mission is aimed at improving patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated, with a significant focus on creating a potent, cost-effective, and convenient LDL-lowering therapy. The company is headquartered in Naarden, the Netherlands, and its shares are listed on the Nasdaq.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage